Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) price on Thursday, July 03, rose 1.14% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $39.91.
A look at the stock’s price movement, the close in the last trading session was $39.46, moving within a range at $39.02 and $39.98. The beta value (5-Year monthly) was 0.242. Turning to its 52-week performance, $60.37 and $29.59 were the 52-week high and 52-week low respectively. Overall, RARE moved 9.64% over the past month.
Ultragenyx Pharmaceutical Inc’s market cap currently stands at around $3.77 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-06.
Analysts have a consensus estimate of 161.67M for the company’s revenue for the quarter, with a low and high estimate of 148M and 174M respectively. The average forecast suggests up to a 9.96% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 649.82M, representing a 15.99% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RARE is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
16 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 14 recommend RARE as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RARE’s current price about 6.68% and 8.60% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 65.01, while 7-day volatility ratio is 5.20% and 4.20% in the 30-day chart. Further, Ultragenyx Pharmaceutical Inc (RARE) has a beta value of 0.26. Analysts have given the company’s stock an average 52-week price target of $89.5, forecast between a low of $64 and high of $115. Looking at the price targets, the low is -60.36% off current price level while to achieve the yearly target high, price needs to move -188.15%. Nonetheless, investors will most likely welcome a -124.25% jump to $89.5 which is the analysts’ median price.
If we refocus on Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), historical trading data shows that trading volumes averaged 1.09 over the past 10 days and 1.07 million over the past 3 months. The company’s latest data on shares outstanding shows there are 93.74 million shares.
The 6.52% of Ultragenyx Pharmaceutical Inc’s shares are in the hands of company insiders while institutional holders own 95.29% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.08 million on 2025-06-13, giving us a short ratio of 5.87. The data shows that as of 2025-06-13 short interest in Ultragenyx Pharmaceutical Inc (RARE) stood at 665.99995 of shares outstanding, with shares short rising to 5.89 million registered in 2025-05-15. Current price change has pushed the stock -2.94% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RARE stock continues to rise going into the next quarter.
